INVA
$22.06
Innoviva, Inc.
Intraday
Recent News
Cantor Fitzgerald Lifts PT on Innoviva, Inc. (INVA) to $32 from $31 – Here’s Why
Innoviva, Inc. (NASDAQ:INVA) is one of the best cheap biotech stocks to buy now. Cantor Fitzgerald lifted the price target on Innoviva, Inc. (NASDAQ:INVA) to $32 from $31 on February 26, maintaining an Overweight rating on the shares. The firm told investors in a research note that the fiscal Q4 revenue of $114.6M surpassed expectations, driven […]
Is It Time To Reassess Innoviva (INVA) After Its Strong Multi Year Share Price Run
If you are wondering whether Innoviva's recent share price puts it on sale or already prices in the story, you are in the right place to get a clear view on what you might be paying for. Innoviva's stock closed at US$22.96, with returns of 14.8% over the last 30 days, 15.6% year to date and 28.1% over the past year, while the 7 day return shows a 1.8% decline and the 3 year and 5 year returns stand at 108.9% and 99.5% respectively. These moves sit against a backdrop of ongoing company...
Innoviva, Inc. (INVA): A Bull Case Theory
We came across a bullish thesis on Innoviva, Inc on Deep-Value Stocks’s Substack. In this article, we will summarize the bulls’ thesis on INVA. Innoviva, Inc’s share was trading at $22.48 as of February 11th. INVA’s trailing and forward P/E were 13.54 and 10.83 respectively according to Yahoo Finance. Innoviva, Inc. engages in the development and commercialization of […]
Innoviva CEO Details 3-Part Growth Plan, $125M Buyback, and 2026 Catalysts at Oppenheimer Conference
Innoviva (NASDAQ:INVA) Chief Executive Officer Pavel Raifeld outlined the company’s evolving business mix, capital allocation priorities, and upcoming catalysts during a conference discussion hosted by Oppenheimer analyst Trevor Allred. Raifeld said Innoviva has moved beyond its origins as a royalty
Celldex Therapeutics Stock Earns 88 RS Rating
On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against that of all other stocks. Is Celldex Therapeutics Stock A Buy?